Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Cash from Investing Activities: 2024-2025

Historic Cash from Investing Activities for Kura Oncology (KURA) over the last 2 years, with Sep 2025 value amounting to $94.0 million.

  • Kura Oncology's Cash from Investing Activities rose 106.36% to $94.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$43.5 million, marking a year-over-year change of. This contributed to the annual value of -$101.6 million for FY2024, which is 753.02% down from last year.
  • Latest data reveals that Kura Oncology reported Cash from Investing Activities of $94.0 million as of Q3 2025, which was up 59.42% from $58.9 million recorded in Q2 2025.
  • Kura Oncology's 5-year Cash from Investing Activities high stood at $94.0 million for Q3 2025, and its period low was -$101.4 million during Q1 2025.
  • Over the past 2 years, Kura Oncology's median Cash from Investing Activities value was $43.2 million (recorded in 2024), while the average stood at -$7.2 million.
  • Data for Kura Oncology's Cash from Investing Activities shows a peak YoY increase of 106.36% (in 2025) and a maximum YoY decrease of 6.37% (in 2025) over the last 5 years.
  • Quarterly analysis of 2 years shows Kura Oncology's Cash from Investing Activities stood at -$95.0 million in 2024, then surged by 106.36% to $94.0 million in 2025.
  • Its Cash from Investing Activities stands at $94.0 million for Q3 2025, versus $58.9 million for Q2 2025 and -$101.4 million for Q1 2025.